Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Evaluates Cosmetic Lens Manufacturer Claims; UK Weighs Regulation

This article was originally published in The Gray Sheet

Executive Summary

Fashion Wear Services, Ltd.'s appeal to FDA to regulate colored, noncorrective (plano) contact lenses as cosmetics coincides with UK efforts to legislate oversight of the products
Advertisement

Related Content

Optometrists, Legislators Push For Stronger FDA Oversight Of Contact Lenses
Optometrists, Legislators Push For Stronger FDA Oversight Of Contact Lenses
Plano Lens Cosmetics Classification Countered In Boozman-Waxman Bill
Plano Lens Cosmetics Classification Countered In Boozman-Waxman Bill
Regulatory News In Brief
Regulatory News In Brief
Plano Contact Lens Warning Indicates Continued FDA Regulation As Devices
Plano Contact Lens Warning Indicates Continued FDA Regulation As Devices
McClellan Outlines Vision For Device User Fees, Third-Party Inspections
Noncorrective contact lens distribution
Advertisement
UsernamePublicRestriction

Register

MT017085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel